drugset / Trial / NCT01777776
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.
Timeline
- Start
- 2013-07
- Primary completion
- 2015-04
- Completion
- 2015-04
Outcome
Outcome not reported
Stopped (Business): “Study was withdrawn due to scientific and business considerations.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Encorafenib | Small molecule | — | Oral |
| Subject | Ribociclib | Small molecule | — | Oral |